This trial is evaluating an investigational drug in adults with moderate to severe tremor due to Parkinson’s disease. You may be able to take part in this trial if you:
Are 40 to 85 years of age
Have been diagnosed with Parkinson's disease
Participation lasts up to 23 weeks, which includes a screening period of up to 4 weeks, a 5-week period to find the optimal dose of the investigational drug, a 12-week maintenance period, and a 2-week safety follow-up period. The trial involves approximately 9 visits to the trial center, including 1 screening visit, and 11 phone calls with the trial team. Participants are randomly assigned to 1 of 2 groups. They receive either the investigational drug or a placebo (a substance that looks like the investigational drug but contains no medicine), both taken orally (by mouth).
If eligible, participation can last up to about 23 weeks, which includes 9 visits to the trial center, including 1 screening visit, and 11 phone calls with the trial team.
The investigational drug is a capsule that is taken orally (by mouth).
Do not discontinue any prescription and over-the-counter medications and/or supplements unless you are advised to do so by the trial center staff or your primary care provider.
There is no cost to you for participating in the trial.
Clinical trials are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this trial. This does not mean you will not qualify for different trials.
This trial is evaluating an investigational drug in adults with moderate to severe tremor due to Parkinson’s disease. You may be able to take part in this trial if you:
Are 40 to 85 years of age
Have been diagnosed with Parkinson's disease
Participation lasts up to 23 weeks, which includes a screening period of up to 4 weeks, a 5-week period to find the optimal dose of the investigational drug, a 12-week maintenance period, and a 2-week safety follow-up period. The trial involves approximately 9 visits to the trial center, including 1 screening visit, and 11 phone calls with the trial team. Participants are randomly assigned to 1 of 2 groups. They receive either the investigational drug or a placebo (a substance that looks like the investigational drug but contains no medicine), both taken orally (by mouth).
If eligible, participation can last up to about 23 weeks, which includes 9 visits to the trial center, including 1 screening visit, and 11 phone calls with the trial team.
The investigational drug is a capsule that is taken orally (by mouth).
Do not discontinue any prescription and over-the-counter medications and/or supplements unless you are advised to do so by the trial center staff or your primary care provider.
There is no cost to you for participating in the trial.
Clinical trials are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this trial. This does not mean you will not qualify for different trials.
We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
For more detailed information on the cookies we use, please check our Privacy Policy.
By continuing to access this website, you are giving us consent to collect cookies.
